Search

Displaying results 9661 - 9670 of 10000 in total
  1. Drug

    Nimorazole

    go.drugbank.com/drugs/DB12172
    Investigational

    Nimorazole has been used in trials studying the treatment of Hypoxia, Radiotherapy, Hypoxic Modification, Gene Profile, Gene Signature, and Head and Neck Squamous Cell Carcinoma, among others.

  2. Drug

    Idasanutlin

    go.drugbank.com/drugs/DB12325
    Investigational

    Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia

  3. Drug

    GSK-356278

    go.drugbank.com/drugs/DB12542
    Investigational

    Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others

  4. Drug

    RD13-02

    go.drugbank.com/drugs/DB27110
    Investigational

    RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).

  5. Drug

    Estradiol sulfamate

    go.drugbank.com/drugs/DB06597
    Investigational

  6. Drug

    Ilepatril

    go.drugbank.com/drugs/DB06604
    Investigational

  7. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  8. Drug

    Flovagatran

    go.drugbank.com/drugs/DB05714
    Experimental

  9. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...

  10. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.